SCHEMBL12786355

SCHEMBL12786355

CCCCOCn1cnc2c(=O)[nH]c(N)nc21

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNP P00491 8/20 0.76
HBB P68871 2/20 0.76
BLM P54132 2/20 0.76
USP2 O75604 1/20 0.76
TSHR P16473 1/20 0.76
EDNRA P25101 1/20 0.76
HTR2A P28223 1/20 0.76
RECQL P46063 1/20 0.76
HSD17B10 Q99714 1/20 0.76
HPRT1 P00492 4/20 0.72
MEN1 O00255 3/20 0.64
KMT2A Q03164 3/20 0.64
MAPK1 P28482 1/20 0.62
POLG P54098 1/20 0.62
ALDH1A1 P00352 1/20 0.59
LMNA P02545 1/20 0.59
CYP3A4 P08684 1/20 0.59
NFKB1 P19838 1/20 0.59
VCP P55072 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28721440 0.95 PNP (0.73) PNPHBBBLMUSP2TSHR
SCHEMBL8665621 0.94 PNP (0.71) PNPHBBBLMUSP2TSHR
SCHEMBL10421280 0.93 PNP (0.79) PNPHBBBLMUSP2TSHR
SCHEMBL8445570 0.90 PNP (0.76) PNPHBBBLMUSP2TSHR
SCHEMBL29370760 0.90 PNP (0.87) PNPHBBBLMUSP2TSHR
SCHEMBL9463793 0.89 BLM (0.67) PNPHBBBLMUSP2TSHR
Acyclovir SCHEMBL16062041 0.88 PNP (0.79) PNPHBBBLMUSP2TSHR
SCHEMBL8380760 0.88 PNP (0.88) PNPHBBBLMUSP2TSHR
Acyclovir SCHEMBL9479083 0.88 PNP (0.93) PNPHBBBLMUSP2TSHR
SCHEMBL12786353 0.88 PNP (0.57) PNPHBBBLMUSP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110059921-A1 Oligomer-Nitrogenous Base Conjugates Ektar Therapeutics (US) 2011-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059921-A1 Oligomer-Nitrogenous Base Conjugates NCL, NMBR, SLC43A3 PNP 1022/4885HBB 1329/4885BLM 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.